Exchange: OTC·Updated 03:47 PM EST

MDNAF Medicenna Therapeutics Corp

$0.1228
$0.0172
(12.29%)
Today
Reported EarningsNov 17
Mkt Cap$9.53M
Vol195,609.00

About MDNAF

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
51

Neutral Sentiment

How do you feel about MDNAF?

DIJG
$MDNAF Exceptional result. I'm pleased the market isn't punishing the stock, even if the share price hasn't yet responded the way many expected. Price action can lag reality, but eventually the value of strong clinical data tends to be recognized. The key risk was always whether the drug could generate meaningful efficacy. That question has now been answered. From here, the focus shifts to regulatory execution: defining the registrational pathway, meeting with the FDA, and aligning on Project Optimus requirements. A partnership deal will likely hinge on those discussions, but with data of this quality, MDNA11 has become very difficult for the industry to ignore.
14
Itsybitsybeanbag
$MDNAF HAPPY WEEKEND YA’LL Fingers crossed for good stuff tomorrow…data that’s great for us and greater for patients !!
12
DIJG
$MDNAF When a biotech moves from a volatile, headline-chasing retail vehicle to a fundamentally de-risked story with a validated clinical asset, the shareholder base rotates. Retail momentum traders seeking an overnight spike exit into the liquidity provided by the data drop while some mid-tier funds accumulate. Retails cannot re-rate a stock Deals rarely happens immediately on data drop bcos big pharma/ institutional funds still need to perform their internal review of data which requires deep dataset modeling, validation of response durability, and strategic due diligence. While they crunch the numbers, the focus shifts to the corporate side. Dr. Nageatte Ibrahim and the clinical team cannot afford any lag at this time. Translating the data into a locked-down, statistically powered registration protocol is required to walk into the FDA briefing room with authority.
10
RAW4111
$MDNAF Paraphrase from Dr. Tawbi presentation this morning.. 'MDNA11 is what we have been waiting for in the IL space'
9
DIJG
$MDNAF Ahead of his MDNA11 oral presentation tomorrow at SITC, Prof. Ascierto receiving his SITC Lifetime Achievement award today at SITC
9
ewll
$MDNAF Paolo Ascierto, 2026 SITC Lifetime Achievement Award winner, will be the presenter for MDNA11 @ SITC 2026!
9
Rayvio_News_Filter
$MDNAF 🏥 Medicenna Therapeutics presented ABILITY-1 data at SITC 2026 showing MDNA11 achieved a 40% objective response rate (8/20) and 80% disease control rate (16/20) in efficacy-evaluable MSI-H or MSS TMB-H gastrointestinal cancers resistant to approved therapies. Market-relevant event
8
RAW4111
$MDNAF A classic example of the volatility of illiquid small cap bio-tech's where trading less than 1% of the outstanding shares can impact and reduce the market cap of the company by over 40%. It can work the other way, but not today! To the Board of MDNA....This is too big and to good to do on our own...Let's get a deal DONE!
7
RAW4111
$MDNAF great find. In plain English: In patients with recurrent glioblastoma (a highly aggressive brain cancer that has come back) that could not be surgically removed, and whose tumors had the normal (non-mutated) form of the IDH gene, treatment with the experimental drug bizaxofusp at the recommended Phase 3 dose led to a clear improvement in overall survival compared with a carefully matched group of similar contemporary patients who received standard care (an external control arm). The survival benefit was seen even without selecting patients based on whether their tumors expressed high levels of the IL-4 receptor (the target of the drug). This supports moving the drug into a registrational (approval-seeking) Phase 3 trial. Now the key question, before everyone jumps onblard. How/who will pay for the Phase 3 trial?
7
Itsybitsybeanbag
$MDNAF WTX-124 abstract is out…. supposedly late-breaking…meh I don’t see anything to write home about other than what was already known about their study… last update, April 2026
7
Itsybitsybeanbag
$MDNAF Fahar better not do a r/s with this response , it’ll drop back to Pennie’s in a heartbeat
1
3
Allstarbd1988
$MDNAF I think we will get the announcmet NEO-CYT will be presenting data at the 2026 Melanoma Bridge program sometime between Oct 30th - Nov 6th. NEO-CYT is sponsored by Fondazione Melanoma Onlus, led by Paolo Ascierto in Naples, and Melanoma Bridge is organized on behalf of Fondazione Melanoma Onlus Abstract submission deadline: October 5 Acceptance notification: October 30 Conference: December 1–3
6
Biostockfollower
$MDNAF he has to say something soon. I’ve been a huge bull for this over the last several years and am thinking about calling it. I have so much money tied into it though lol
4
Lytnup
$MDNAF I think he knows it - FWIW, 400K shares traded, and the price didn’t drop like a rock. Someone may quietly be accumulating off of the tax loss / disheartened sellers.
4
bobwut12
$MDNAF At this point I feel like Medicenna could come out with news that they've literally cured cancer and death itself and we still wouldn't be back to our NASDAQ glory days prices. We need some kind of financial announcement, be it a partnership or a deal. If a reverse split does actually happen and it's not for the purposes of uplisting back to the NASDAQ, then we could have endless great scientific and medical news and still end up penniless (like with Briacell). Please please don't screw this up Dr. Fahar
4
Rayvio_News_Filter
$MDNAF 🏥 Medicenna Therapeutics Corp. announced new preclinical data showing MDNA209 achieved potent CD122 blockade and extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease. Curated for market relevance
4
NewbJackCity
$MDNAF Checking back in. Wow! I would ask what happened, but I’m guessing they released more good data. This fits the pattern of their past 20 data releases.
3
Lytnup
$MDNAF Sorry guys - that was me bid-sitting at .32, and was filled at .31. Against my better judgment, I will continue to do so as funds allow. I hope everyone has a peaceful and restorative weekend, as we inch closer to more news and data.
3
_Osmium
$MDNAF About $5000 has taken this company down by 20%. Put another way, a 5 million market cap drop costs just 5000 to implement. Absurd.
2
Lytnup
$MDNAF Is it just me, or do Medicenna employees seem to comment / like / celebrate everyone else’s accomplishments but their own company’s on Linked In? Come on, Dr. Ibrahim! Let’s see some esprit de corps as Medicenna’s CMO,for crying out loud!
2

Advertisement|Remove ads.